Allergy Therapeutics Live Discussion

d_gaser 17 Oct 2018

Why such a big share price drop? It seems strange that after the company issued such a bullish statement and raised extra cash, the price has now fallen by over 25% . Have the Board duped us ,or doe’s the market know some thing ? What ever it is ,it looks as though the old days when Medisys invested here have returned ,it now appears a low S.P,and fears for our future are here again . BE HAPPY DAVE

Dino78 26 Sep 2018

TV Clip Morning. Short TV interview with the guys following this morning’s results announcement: Five Minute Pitch TV – 26 Sep 18 Increased Market Share and Revenues at Allergy Therapeuticsvv Allergy Therapeutics plc (LON:AGY) today released Preliminary Results for the year ended 30th June 2018. European market share for their products has increased by 1% to 14%, whilst revenues have grown by 6.6% to £68.3m (2017:£64.1m). An investor...

Totally_Wired 12 Jul 2018

Trading update-Group's market share continues to grow 12 July 2018 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today provides a trading update for the year ended 30 June 2018 ahead of its Preliminary Results to be announced in September. Financials Revenues for the year are expected to be in line with market expectations at £68.3m (2017: £64.1m). This performance represents 6.6% annual growth on a reported basis and 3.5% on a constant currency basis which reflects a strong performance during an unusually weak pollen season in 2017. The Group is continuing to gain market share within its core markets in Europe and data for the key markets for the 9 months ending 31 March 2018 showed an increase of 0.7 of a market share point1. Expenses are expected to be in line with market expectations due to continuing cost control. The cash balance at the end of June 2018 was £15.5m (30 June 2017: £22.1m). Pipeline Following the positive Grass Phase II trial, the ongoing pipeline trials continue to progress well and timing remains in line with the Group’s strategy. The results of the pivotal Birch Phase III trial for Europe continue to be expected in Q3 2018. Manuel Llobet, CEO at Allergy Therapeutics, stated: “Our convenient, flexible and varied product portfolio has enabled us over the past 19 years to grow revenues at 10% compound annual growth rate. We are pleased that we have continued to make headway in market share this year, despite a poor pollen season, and have maintained a tight control on costs in the period. Our pipeline continues to progress well, with the announcement of excellent Grass Phase II results, the publication of significant papers on the long-term effect of our product and the positive Birch Phase II Trials. We are looking forward to the results of the Birch Phase III trial, expected in Q3 2018.” 1Market data and internal estimates for 9 months to 31 March 2018, for the core European markets in which Allergy Therapeutics operates excluding Switzerland (competitor data not available) [link]

d_gaser 25 Jun 2018

Dustmite study Allergy Therapeutics Reveals Good Results From Dust Mite Allergy Tests by Alliance News | 29th May 2018 11:19 Biotechnology firm Allergy Therapeutics PLC said it will present positive new data on its dust mite allergy treatment at a congress in Germany on Tuesday. Allergy said its house dust mite product is sold in a named patient programme in Spain. In the study across 10 sites in the country 43% of the 141 patients tested showed a decline in symptoms after one year. Further, 17% of an asthmatic subgroup showed more moderate symptoms compared to the 51% baseline. Allergy said no patients had any serious adverse side effect nor did any have to stop treatment during testing. FULL ARTICE FOLLOW LINK Be happy Dave www.ii.co.uk/news/allergy-therapeutics-reveals-good-results-from-dust-mite-allergy-tests-al1527589147663979900/

Totally_Wired 25 Jun 2018

Observational study published 25 June 2018 Allergy Therapeutics plc Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy 25 June 2018 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces the publication of positive data in the journal Immunotherapy, demonstrating long-lasting efficacy of Pollinex Quattro Grass in patients with grass pollen allergy. Zielen et al., Long-term effect of monophosphoryl lipid A adjuvanted specific immunotherapy in patients with grass pollen allergy. doi; 10.2217/imt-2018-0004 (ePub ahead of print). The observational study, led by Professor Stefan Zielen of the Goethe University, Germany, focused on the long-term efficacy of Pollinex Quattro Grass. Each of the clinical symptoms (runny nose, sneezing and conjunctivitis) were statistically significantly reduced in treated patients compared with controls without allergen-specific immunotherapy. The study concluded that patients treated with Pollinex Quattro Grass vaccine exhibited significant and long-lasting symptom improvements 3-6 years after cessation of treatment. Professor Stefan Zielen, author of the paper commented; “We are delighted with the publication of our observational study that demonstrates the long-term effects of Pollinex Quattro Grass immunotherapy. Our paper highlights the benefits that this allergen-specific immunotherapy can offer allergy sufferers, in terms of patient convenience, as well as the potential for positive and long-lasting effects.” Manuel Llobet, CEO at Allergy Therapeutics, said: “This paper validates earlier studies indicating Pollinex Quattro is disease modifying for the many patients affected by grass allergy. Together with the recently announced positive data from our Phase Grass G205 clinical study, we believe that we have a robust data set for our suite of novel allergy product candidates. We look forward to commencing further studies with the goal of developing a strong allergy portfolio to patients globally, including in the significant US market.” The data presented supports earlier studies investigating Pollinex Quattro, Zielen et al., 20071 and Rabe et al 20172. Sustained efficacy according to European Medicine Agency criteria in 3114 patients was shown in the 2007 Zielen paper1, where after 3 years, improvement of symptoms was reported in more than 93% of patients and the consumption of anti-allergic medication decreased in more than 75% of patients. [link]

d gaser 30 May 2018

Dust mite Immunotheropy well tolerated (GlobeNewswire) - Allergy Therapeutics plc("Allergy Therapeutics", the Group or Company"Positive new clinical data with house-dust mite immunotherapy~ House-dust mite immunotherapy shown to be well-tolerated and demonstrates highly significant symptom improvement ~~ Allergy experts present an overview of adjuvants at satellite symposium during EAACI 2018 ~29 May 2018Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces positive new data on its wholly-owned modified house-dust mite subcutaneous immunotherapy1. This data will be presented today at the 37thAnnual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) in Munich, Germany.The Groups modified house-dust mite product sold as through a Named Patient Program in Spain, is the precursor to the modified house-dust mite + MPL product currently in Phase I, as announced in February 2017.In this observational study conducted in 10 sites across Spain, 141 patients were evaluated and demonstrated a 43% decrease in combined symptom medication score compared with baseline after one year (p =

Baffler 29 May 2018

How long can Allergy Therapeutics last? Underestimate what this team are doing at your peril! impo/dyor...The day will come when this business will be snapped up.....after stage 3, I suspect! Allergy Therapeutics PLC 29 May 2018 Allergy Therapeutics plc ("Allergy Therapeutics", the "Group" or "Company" Positive new clinical data with house-dust mite immunotherapy House-dust mite immunotherapy shown to be well-tolerated and demonstrates highly significant symptom improvement Allergy experts present an overview of adjuvants at satellite symposium during EAACI 2018 29 May 2018 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces positive new data on its wholly-owned modified house-dust mite subcutaneous immunotherapy(1) . This data will be presented today at the 37(th) Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) in Munich, Germany. The Group's modified house-dust mite product sold as through a Named Patient Program in Spain, is the precursor to the modified house-dust mite + MPL product currently in Phase I, as announced in February 2017. In this observational study conducted in 10 sites across Spain, 141 patients were evaluated and demonstrated a 43% decrease in combined symptom medication score compared with baseline after one year (p = <0.0001). In addition, in a subgroup of asthmatic subjects, 16.7% of patients were observed with moderate persistent asthma at one year compared with 50.9% at baseline (p = <0.01). No patients presented with serious adverse events and no patients had to stop treatment due to any adverse event. Allergy Therapeutics also presented a series of poster presentations at EAACI with key highlights including an overview of the early-phase pre-clinical developments for the Group's planned recombinant peanut vaccine(3) and a discussion of the results of a non-interventional study investigating rapid up-dosing of tree sublingual immunotherapy(4) . Other events held by the Group at EAACI included a satellite symposium entitled: "Adjuvants through the ages"(2) which provided a summary of how adjuvant technologies have evolved and how Allergy Therapeutics is spearheading the design and testing of state of the art allergen-specific immunotherapies. Manuel Llobet, Chief Executive Officer, commented: "We are excited to be sharing our latest research at EAACI, demonstrating the breadth of our unique allergen immunotherapy company. The positive new data on our modified house-dust mite immunotherapy and our recent announcement on the success of our Grass G205 dose-finding clinical study confirms that our novel allergen-specific immunotherapies are formulated to the optimal strength, and we believe Allergy Therapeutics has the potential to transform allergy treatment with optimised-dose, well-characterised, aluminium-free, convenient products."

Baffler 29 May 2018

How long can Allergy last? Underestimate what this team our doing at your peril! impo/dyor...The day will come when this business will be snapped up.....after stage 3, I suspect! Allergy Therapeutics PLC 29 May 2018 Allergy Therapeutics plc ("Allergy Therapeutics", the "Group" or "Company" Positive new clinical data with house-dust mite immunotherapy House-dust mite immunotherapy shown to be well-tolerated and demonstrates highly significant symptom improvement Allergy experts present an overview of adjuvants at satellite symposium during EAACI 2018 29 May 2018 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces positive new data on its wholly-owned modified house-dust mite subcutaneous immunotherapy(1) . This data will be presented today at the 37(th) Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) in Munich, Germany. The Group's modified house-dust mite product sold as through a Named Patient Program in Spain, is the precursor to the modified house-dust mite + MPL product currently in Phase I, as announced in February 2017. In this observational study conducted in 10 sites across Spain, 141 patients were evaluated and demonstrated a 43% decrease in combined symptom medication score compared with baseline after one year (p = <0.0001). In addition, in a subgroup of asthmatic subjects, 16.7% of patients were observed with moderate persistent asthma at one year compared with 50.9% at baseline (p = <0.01). No patients presented with serious adverse events and no patients had to stop treatment due to any adverse event. Allergy Therapeutics also presented a series of poster presentations at EAACI with key highlights including an overview of the early-phase pre-clinical developments for the Group's planned recombinant peanut vaccine(3) and a discussion of the results of a non-interventional study investigating rapid up-dosing of tree sublingual immunotherapy(4) . Other events held by the Group at EAACI included a satellite symposium entitled: "Adjuvants through the ages"(2) which provided a summary of how adjuvant technologies have evolved and how Allergy Therapeutics is spearheading the design and testing of state of the art allergen-specific immunotherapies. Manuel Llobet, Chief Executive Officer, commented: "We are excited to be sharing our latest research at EAACI, demonstrating the breadth of our unique allergen immunotherapy company. The positive new data on our modified house-dust mite immunotherapy and our recent announcement on the success of our Grass G205 dose-finding clinical study confirms that our novel allergen-specific immunotherapies are formulated to the optimal strength, and we believe Allergy Therapeutics has the potential to transform allergy treatment with optimised-dose, well-characterised, aluminium-free, convenient products."

Baffler 22 May 2018

I.C. VIEW Shares remain under priced BUY at 27p

Dino78 22 May 2018

TV Clip Afternoon,Short TV interview with both CEO Manuel Llobet and House broker Panmure Gordon's Healthcare Analyst Dr Mike Mitchell[link]

d gaser 21 May 2018

New hardman research paper on AGY Today Hardmen have released a new research paper on AGY follow link for the full paper BE HAPPYDAVE 21 May 2018 12:25:12Hardman & Co Research: Allergy Therapeutics (AGY): Opening the door to registration21-May-2018 / 12:25 GMT/BST[link]

d gaser 21 May 2018

Grass MATA MPL Phase II study meets end point This is great news ,and should start pushing the S/P north BE HAPPYDAVE 21 May 2018 070:10Allergy TherapeuticsRNS Number : 6504OAllergy Therapeutics PLC21 May 2018 Allergy Therapeutics plc("Allergy Therapeutics" or the "Group" Allergy Therapeutics announces positive top-line results from its Grass MATA MPLPhase II dose ranging study - Primary endpoint met with highly statistically significant dose-response relationship established - - Optimal Phase III dose identified - - Phase III study due to commence in 2019 - 21 May 2018 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces highly positive top-line results from its Grass Modified Allergen Tyrosine Absorbed (MATA) MPL Phase II dose ranging study (G205). The trial met its primary endpoint of establishing a dose-response relationship and a Phase III dose. Approximately 30% of the population in Europe and 25% of the population of the US are allergic to grass pollen1, one of the most prevalent global aeroallergens. The key results announced today:· Primary endpoint of the trial met with highly statistically significant dose-response relationship (p<0.0001) · All dosing regimens were safe and well tolerated· The currently marketed product showed a significant improvement compared to placebo (p<0.01)· Significant increase in immunoglobulin results, highly consistent with the dose response observed for the primary endpoint· Adherence to the short treatment course was excellent. More than 95% of patients received the target cumulative dose during six weekly subcutaneous injections The G205 trial is a multi-centre, double-blind, placebo controlled study designed to explore the safety and response of different cumulative doses of Grass MATA and MPL for grass-pollen induced seasonal allergic rhinitis. The European study took place in Germany, Poland and Austria and 447 patients were randomised into four active arms plus a placebo, evaluating the change in allergic symptoms as determined by the total symptom score (TSS) following conjunctival provocation test (CPT) with the objective to achieve a dose recommended for Phase III development. Manuel Llobet, CEO at Allergy Therapeutics, stated: "We are thrilled with these extremely positive results demonstrating dose dependent efficacy of the product including the current marketed dose. This study represents a major milestone in our path forward to a registered grass allergy product in Europe. Additionally, this brings us closer towards marketing authorisation in the estimated $2bn US allergy market, a significant opportunity where our product has the potential to be the first registered subcutaneous immunotherapy for the treatment of grass allergy. With an optimal dose identified, we look forward to sharing this new, exciting data with the health authorities and plan to commence a Phase III study in 2019.

Totally Wired 14 May 2018

The Journal of Immunology 16 March 2018Allergy Therapeutics plcDirector/PDMR Shareholding Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that, on 15 March 2018, Tunde Otulana, Non-Executive Director of the Company, purchased 25,000 ordinary shares of 0.1p in the Company ("Ordinary Shares" at a price of $0.388 per Ordinary Share (equivalent to 27.8p per Ordinary Share)*. Mr Otulana's total beneficial holding now amounts to 50,000 Ordinary Shares, which represents 0.01% of the issued share capital of the Company to which voting rights are attached.[link] View banjomick's profile - 14 May 2018 086 - 131 of 131 edit this post14 May 2018Allergy Therapeutics plcAllergy Therapeutics Publishes New Data Validating Mode of Action and Unique Adjuvant Properties of its Patented Adjuvant, Microcrystalline Tyrosine (MCT®, in The Journal of Immunology Novel Findings Further Highlight the Effectiveness of MCT as Alternative to Alum and its Potential Advantage in Allergy-Specific ImmunotherapyWORTHING, United Kingdom, 14 May 2018 - Allergy Therapeutics (AIM:AGY), a leading, fully-integrated commercial biotechnology company specialising in allergy vaccines, today announces that new data from a study investigating immune responses produced by microcrystalline tyrosine (MCT®-based vaccines as compared with conventional aluminium hydroxide has been published online in The Journal of Immunology. The findings demonstrate that, based on its comparable strength and mechanism of Ag-specific IgG induction and induction of T cell responses, MCT® is a suitable and flexible alternative to aluminium hydroxide as an adjuvant in both allergen-specific immunotherapy and infectious disease applications. The study also demonstrated that MCT®-adjuvanted allergens caused fewer anaphylactic reactions compared with alum-adjuvanted allergens. "These findings provide evidence of the effectiveness of MCT as an adjuvant, confirming the mechanism of action underlying its ability to induce a robust and sustained immunological response. Additionally, the findings indicated a potentially favourable profile for the use of MCT over alum in allergy-specific vaccines," said Matthias Kramer, M.D., Allergy Therapeutics' International Medical Director and co-author of the paper. "We believe these data highlight the significance of our differentiated proprietary platform technology in the development of our growing suite of cutting-edge, globally marketed ultra-short course allergy vaccines."This is the first study to report the mechanism of action by which MCT governs the immunologic response after exposure to an antigen and protection against anaphylaxis in an allergic model. The results illustrate upregulation of IgG antibody responses and a higher IgE:IgG ratio in MCT-based immunotherapy compared with Alum-based immunotherapy. A high IgE:IgG ratio has been reported to be a positive predictive marker for allergen immunotherapy in humans. Further evaluation in this study indicated that MCT facilitates robust adaptive T cell responses with associated IFN-ã (interferon gamma) and TNF-á (tumour necrosis factor alpha), which is in line with previous studies illustrating protective efficacy in influenza and malaria applications1, 2. Meanwhile, studies in a cancer (melanoma) model are underway.A link to publication is here: www.jimmunol.org/content/200/9/3151

cloakey 11 May 2018

so whats the latest Is this fall down to Brexit or are there some failures I`m not aware of

d gaser 11 Apr 2018

Director buys 25,000 shares on the open market AGY needs to see more directors like Otulana backing this company by buying shares in the company on the open market. This purchase shows that this particular board member has confidence in AGY future growth potential, and I for one welcome that, now lets hope others follow him BE HAPPYDAVE . Allergy Therapeutics plc("Allergy Therapeutics" or the "Company" Director/PDMR Shareholding Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that, on 15 March 2018, Tunde Otulana, Non-Executive Director of the Company, purchased 25,000 ordinary shares of 0.1p in the Company ("Ordinary Shares" at a price of $0.388 per Ordinary Share (equivalent to 27.8p per Ordinary Share)*. Mr Otulana's total beneficial holding now amounts to 50,000 Ordinary Shares, which represents 0.01% of the issued share capital of the Company to which voting rights are attached.